AstraZeneca, Boehringer Ingelheim, Eli Lilly, J&J, Mitsubishi Tanabe Pharma sales and marketing update

The agency said the drugs had incremental cost-effectiveness ratios (ICERs) per quality adjusted life year (QALY) of L20,000-L30,000

Read the full 186 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE